TriLink's patented CleanCap® Reagent M6 [CleanCap m6AG (3′ OMe)], is designed for the co-transcriptional capping of mRNA to produce an mRNA with base-modified Cap 1. Cap-1 mRNAs have superior in vivo activity compared to Cap-0 mRNAs produced by legacy capping methods.

• Most robust CleanCap cap analog to date for co-transcriptional mRNAcapping

  Increases protein expression by up to >30% compared to enzymatic capping

  Grade: RUO

Design: The addition of a methyl group on position 6 of the first adenosine (m6A) may further increase protein expression relative to CleanCap AG or CleanCap AG (3′OMe). It has been hypothesized that the m6A modification adjacent to the 7-methylguanosine cap can positively influence mRNA stability by preventing enzyme-mediated decapping (Mauer et al. 2017)​.

Usage: CleanCap M6 uses the same 5′ AG initiation sequence as CleanCap AG and CleanCap AG (3′OMe). For optimal results, use the Clean M6–specific IVT transcription buffer and the cap analog’s concentration specified in the product insert. CleanCap M6 can be used in conjunction with TriLink’s modified and unmodified nucleotides, as well as IVT enzymes.

Performance: The optimised standard-yield protocol produces >95% capping efficiency and typical crude yields of 4 to 5 mg/ml of mRNA from in vitro transcription (IVT).​ The additional high-yield pulse-feed protocol is also included to provide up to 2x mRNA yields without impacting mRNA quality attributes.